Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | HCRTR1 | O43613 | 16/20 | 0.43 |
| ▸ | HCRTR2 | O43614 | 16/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22018199 | 1.00 | KDM4E (0.44) | KDM4EHSD17B10USP2HPGDNPSR1 | |
| SCHEMBL27452742 | 0.81 | KDM4E (0.45) | KDM4EHSD17B10USP2HPGDNPSR1 | |
| SCHEMBL24192466 | 0.81 | HCRTR2 (0.35) | HCRTR1HCRTR2 | |
| SCHEMBL22018858 | 0.77 | HCRTR1 (0.41) | KDM4EHSD17B10USP2HPGDNPSR1 | |
| SCHEMBL22018202 | 0.72 | ALDH1A1 (0.51) | KDM4EHSD17B10HPGDHCRTR1HCRTR2 | |
| SCHEMBL22018189 | 0.72 | ALDH1A1 (0.51) | KDM4EHSD17B10HPGDHCRTR1HCRTR2 | |
| SCHEMBL24192976 | 0.72 | HCRTR1 (0.49) | KDM4EHSD17B10USP2HPGDNPSR1 | |
| SCHEMBL1670922 | 0.71 | HCRTR1 (0.51) | HCRTR1HCRTR2 | |
| SCHEMBL29117985 | 0.71 | HCRTR1 (0.51) | HCRTR1HCRTR2 | |
| SCHEMBL21963537 | 0.71 | HCRTR1 (0.51) | HCRTR1HCRTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020100011-A1 | IMPROVED SYNTHETIC METHODS OF MAKING FUSED HETEROCYCLIC COMPOUNDS AS OREXIN RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2020-05-22 | — | — | WO | disclosed |